|
Squamous cell carcinoma of oropharynx
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patients with oropharyngeal squamous cell carcinoma (OPSCC) treated with intensity-modulated radiotherapy (IMRT) were stratified by p16 status, neck dissection, and chemotherapy to correlate these factors with outcomes.
|
20225325 |
2010 |
|
Squamous cell carcinoma of oropharynx
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Exons 1-3 of the p16 and exon 2 of the p21 genes were examined for mutations by polymerase chain reaction (PCR)/direct DNA sequencing methods in 21 fresh-frozen tissue specimens of oropharyngeal SCCs previously studied for expression and mutation (exons 5-9) of the p53 gene.
|
14981901 |
2004 |
|
Squamous cell carcinoma of oropharynx
|
0.100 |
Biomarker
|
disease |
BEFREE |
The authors explored the prognostic significance of heregulin/HER3 expression in patients with oropharyngeal squamous cell carcinoma (OPSCC), taking into account other HER family members as well as p16 status.
|
26195293 |
2015 |
|
Squamous cell carcinoma of oropharynx
|
0.100 |
Biomarker
|
disease |
BEFREE |
Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.
|
26712222 |
2016 |
|
Squamous cell carcinoma of oropharynx
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prognostic impact of p16 can be emphasized in a subgroup of OSCC patients undergoing surgery.
|
29936482 |
2018 |
|
Squamous cell carcinoma of oropharynx
|
0.100 |
Biomarker
|
disease |
BEFREE |
While widely used, p16 immunohistochemistry is both a sensitive and a specific surrogate marker for oncogenic HPV infection in OPSCC, but not in OSCC.
|
30238467 |
2019 |
|
Squamous cell carcinoma of oropharynx
|
0.100 |
Biomarker
|
disease |
BEFREE |
To examine combined immunoprofiles of epidermal growth factor receptor (EGFR), CD44, and p16 in oropharyngeal squamous cell carcinoma (OPSCC) and to correlate them with radiotherapy treatment outcomes and clinicopathological parameters.
|
30079604 |
2018 |
|
Squamous cell carcinoma of oropharynx
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fixed and fresh-frozen tissue from 108 OPSCC cases were subject to eight possible assay/assay combinations: p16 immunohistochemistry (p16 IHC); in situ hybridization for high-risk HPV (HR HPV ISH); quantitative PCR (qPCR) for both viral E6 RNA (RNA qPCR) and DNA (DNA qPCR); and combinations of the above.
|
21969383 |
2011 |
|
Squamous cell carcinoma of oropharynx
|
0.100 |
Biomarker
|
disease |
BEFREE |
The HPV status of 515 patients with oropharyngeal SCC diagnosed between 1987 and 2010 was determined by HPV E6-targeted multiplex real time polymerase chain reaction assay (PCR) and p16 immunohistochemistry.
|
25521312 |
2016 |
|
Squamous cell carcinoma of oropharynx
|
0.100 |
Biomarker
|
disease |
BEFREE |
Study of the concordance between p16 immunohistochemistry and HPV-PCR genotyping for the viral diagnosis of oropharyngeal squamous cell carcinoma.
|
25687724 |
2015 |
|
Squamous cell carcinoma of oropharynx
|
0.100 |
Biomarker
|
disease |
BEFREE |
This finding indicates that HPV genotyping carries valuable prognostic significance in addition to p16 status and future survival studies of OPSCC should take into account differing HPV genotypes.
|
27688111 |
2016 |
|
Squamous cell carcinoma of oropharynx
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with gray zone squamous cell carcinomas were compared with patients with oral cavity squamous cell carcinoma (OSCC) or oropharyngeal squamous cell carcinoma (OPSCC) and stratified by human papillomavirus (HPV) status that was determined by p16 immunostaining or HPV serology.
|
31282843 |
2019 |
|
Squamous cell carcinoma of oropharynx
|
0.100 |
Biomarker
|
disease |
BEFREE |
We established nomograms for overall survival (OS) and progression-free survival (PFS) in patients with oropharyngeal squamous cell carcinoma (OPSCC) and known HPV-DNA and p16 status, and validated the models in cohorts from high- and low-prevalent HPV countries.
|
29795309 |
2018 |
|
Squamous cell carcinoma of oropharynx
|
0.100 |
Biomarker
|
disease |
BEFREE |
The incidence of oropharyngeal squamous cell carcinoma (OPSCC) has been rising in Western countries and this has been attributed to human papillomavirus (HPV) infection. p16 expression is a marker for HPV infection and p16 positive OPSCC is now recognized as a separate disease entity.
|
29942347 |
2018 |
|
Squamous cell carcinoma of oropharynx
|
0.100 |
Biomarker
|
disease |
BEFREE |
During the study, formalin-fixed, paraffin-embedded OPSCC specimens from Japanese patients were analyzed for HPV DNA by the polymerase chain reaction (PCR) and for the surrogate marker p16 by immuno-histochemistry.
|
24403267 |
2013 |
|
Squamous cell carcinoma of oropharynx
|
0.100 |
Biomarker
|
disease |
BEFREE |
To analyze the impact of tumor p16 status and other clinical factors on the therapeutic decision-making process in patients with oropharyngeal squamous cell carcinoma (OPSCC).
|
29871820 |
2018 |
|
Squamous cell carcinoma of oropharynx
|
0.100 |
Biomarker
|
disease |
BEFREE |
PD-L1 expression on tumor cells correlates with p16 status and advanced nodal status in OPSCC.
|
29440293 |
2018 |
|
Squamous cell carcinoma of oropharynx
|
0.100 |
Biomarker
|
disease |
BEFREE |
We evaluated three commercially available p16 antibody clones (E6H4, JC8 and G175-405) utilizing 199 cases of oropharyngeal squamous cell carcinoma from a tissue microarray, read by three pathologists with three different cutoffs for positivity: any staining, >50% and >75%.
|
28621317 |
2017 |
|
Squamous cell carcinoma of oropharynx
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, there is still a percentage of OPSCCs that are positive for p16 immunohistochemistry (p16 IHC) but lack HPV DNA.
|
24249631 |
2014 |
|
Squamous cell carcinoma of oropharynx
|
0.100 |
Biomarker
|
disease |
BEFREE |
We retrospectively examined survival of 107 patients with locally advanced OPSCC after radiotherapy alone (n = 43) or chemoradiotherapy (n = 64) with respect to tumor p16 and HPV DNA status, using Cox's proportional hazard model.
|
30694402 |
2019 |
|
Squamous cell carcinoma of oropharynx
|
0.100 |
Biomarker
|
disease |
BEFREE |
All patients with p16 positive SCCOPx treated with definitive CRT with cisplatin between 2010 and 2014 at a single institution were retrospectively reviewed.
|
28351577 |
2017 |
|
Squamous cell carcinoma of oropharynx
|
0.100 |
Biomarker
|
disease |
BEFREE |
Risk profiling based on p16 and HPV DNA more accurately predicts location of disease relapse in patients with oropharyngeal squamous cell carcinoma.
|
30657857 |
2019 |
|
Squamous cell carcinoma of oropharynx
|
0.100 |
Biomarker
|
disease |
BEFREE |
We investigated the association between HPV and p16 status and previous results of cervical examinations, including cytological and histological tests, in females with OPSCC.
|
30626248 |
2019 |
|
Squamous cell carcinoma of oropharynx
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunohistochemistry Analysis of CD44, EGFR, and p16 in Oral Cavity and Oropharyngeal Squamous Cell Carcinoma.
|
28397583 |
2017 |
|
Squamous cell carcinoma of oropharynx
|
0.100 |
Biomarker
|
disease |
BEFREE |
High-risk human papillomaviruses (HR-HPV), particularly types 16 and 18, have been found to play an important role in head and neck cancer, including oropharyngeal squamous cell carcinoma (OPSCC) and oral squamous cell carcinoma (OSCC). p16, a cell cycle inhibitor, has been postulated as a surrogate marker for HR-HPV, since p16 is aberrantly overexpressed in such lesions, especially in HR-HPV-positive OPSCC.
|
27644660 |
2016 |